6 completed. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 3 |
Follow MorphoSys AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Tafasitamab, Tafasitamab plus lenalidomide - Diffuse Large B-cell Lymphoma | Phase 1 | Completed | MorphoSys AG | 66 | 2019-12-11 | 2024-10-16 |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343) - Neoplasms | Phase 1 | Completed | Bayer | 173 | 2017-05-26 | 2022-06-30 |
| First in Human of Single and Multiple Doses of MOR106 MOR106 single ascending doses, intravenous, Placebo single ascending doses, intravenous, MOR106 multiple ascending doses, intravenous - Healthy, Dermatitis, Atopic | Phase 1 | Completed | Lakefront Biotherapeutics NV | 81 | 2016-04-01 | 2017-10-05 |
| Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis MOR103, Placebo - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 32 | 2012-01-01 | 2014-11-21 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
| Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis MOR103 - Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | MorphoSys AG | 96 | 2009-12-01 | 2014-10-24 |
Arthritis, Rheumatoid (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Dermatitis, Atopic (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Multiple Sclerosis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Thymoma (1) · Triple Negative Breast Neoplasms (1)
Lenalidomide (2) · Otilimab (2) · Cisplatin (1) · Dexamethasone (1) · Gemcitabine (1) · anetumab ravtansine (1) · felzartamab (1) · pomalidomide (1) · tafasitamab (1)
Germany (4) · Belgium (3) · Austria (2) · France (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · United Kingdom (2) · United States (2) · Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · Hungary (1)
Roman P Korolkiewicz, MD, PhD (2) · Helen Timmis, MBChB (1)
PMID 24534756, PMID 32171061, PMID 37369099, PMID 40802906
2016 (1)